Insider · SEC Forms 3, 4, 5
CIK 1494730
All transactions
Every Form 4 row this person reported, newest first
Insider · SEC Forms 3, 4, 5
Every Form 4 row this person reported, newest first
Fust Matthew K (CIK 1397266) reported 10 SEC Form 4 insider transactions across 3 companies over the past 18 months (most recent 2026-09-01). Recent activity: Sell CRNX (22,836 shares), Sell CRNX (5,925 shares), Buy CRNX (5,925 shares), Buy ATRA (12,000 shares), Buy RARE (7,751 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-01 | Crinetics Pharmaceuticals, Inc. (CRNX) | Director | Sell | 22,836 | $1.9M |
| 2026-09-01 | Crinetics Pharmaceuticals, Inc. (CRNX) | Director | Sell | 5,925 | $503,625 |
| 2026-06-22 | Crinetics Pharmaceuticals, Inc. (CRNX) | Director | Buy | 5,925 | $0 |
| 2026-06-11 | Atara Biotherapeutics, Inc. (ATRA) | Director | Buy | 12,000 | $0 |
| 2026-05-18 | Ultragenyx Pharmaceutical Inc. (RARE) | Director | Buy | 7,751 | $0 |
| 2025-09-30 | Crinetics Pharmaceuticals, Inc. (CRNX) | Director | Buy | 10,000 | $19,100 |
| 2025-09-30 | Crinetics Pharmaceuticals, Inc. (CRNX) | Director | Sell | 16,000 | $716,000 |
| 2025-06-13 | Crinetics Pharmaceuticals, Inc. (CRNX) | Director | Buy | 6,900 | $0 |
| 2025-06-12 | Atara Biotherapeutics, Inc. (ATRA) | Director | Buy | 7,828 | $0 |
| 2025-05-19 | Ultragenyx Pharmaceutical Inc. (RARE) | Director | Buy | 5,740 | $0 |
Source: SEC Form 4 filings · as of 2026-09-01